A randomized phase II trial of nab ‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

ConclusionsThe addition of tarextumab to nab ‐paclitaxel and gemcitabine did not improve OS, PFS, or ORR in first‐line metastatic PDAC, and PFS was specifically statistically worse in the tarextumab‐treated patients.Clinical trial registry noNCT01647828.

Source: Cancer Medicine - July 25, 2019 Category: Cancer & Oncology Authors: Zishuo Ian Hu, Johanna C. Bendell, Andrea Bullock, Noelle K. LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W. Leach, James Sanchez, Davendra P. S. Sohal, John Strickler, Ravindranath Patel, Andrea Wang ‐Gillam, Irfan Firdaus, Kenne Tags: ORIGINAL RESEARCH Source Type: research